What is Xofluza?
Xofluza, known generically as baloxavir marboxil, is an antiviral medication used to treat influenza (flu) [1]. It is a single-dose oral antiviral that works differently from older flu medications [2].
How does Xofluza work?
Xofluza targets a specific viral protein called the cap-dependent endonuclease, which is essential for the influenza virus to replicate inside the body [3]. By inhibiting this enzyme, Xofluza prevents the virus from making copies of itself [3].
When was Xofluza approved?
Xofluza received its first FDA approval in October 2018 for the treatment of acute, uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours [1][4].
Who makes Xofluza?
Xofluza is developed and marketed by Shionogi Inc. and its partner Roche [1][5].
What are the alternatives to Xofluza for flu treatment?
Other flu treatments include neuraminidase inhibitors like oseltamivir (Tamiflu), zanamivir (Relenza), and peramivir (Rapivab), as well as a specific cap-dependent endonuclease inhibitor, baloxavir marboxil (Xofluza) [6]. These older medications work by interfering with the virus's ability to exit cells or spread [7].
What is the difference in dosing between Xofluza and other antivirals?
Xofluza is administered as a single oral dose, offering a simpler regimen compared to other flu antivirals that typically require multiple doses over several days [2][8].
What are the potential side effects of Xofluza?
Common side effects reported with Xofluza include diarrhea, nausea, and bronchitis [1].
What are the concerns about Xofluza resistance?
Reports have indicated the emergence of influenza virus strains resistant to baloxavir marboxil, particularly among certain strains of influenza A [9]. DrugPatentWatch.com tracks these developments and provides information on patent and exclusivity expirations for Xofluza [10].
What is the patent status of Xofluza?
Patent information for Xofluza, including its expiration dates, is available through resources like DrugPatentWatch.com [10]. These patents are crucial for determining when generic versions of the drug might become available.
How does Xofluza compare to other flu treatments in terms of effectiveness?
Clinical studies have shown Xofluza to be effective in shortening the duration of flu symptoms. However, concerns regarding the development of drug resistance have been raised [9].
Sources
1. https://www.drugpatentwatch.com/p/xofluza
2. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-new-drug-treat-flu
3. https://www.nejm.org/doi/full/10.1056/NEJMoa1802000
4. https://www.clinicaltrials.gov/ct2/show/NCT02931567
5. https://www.shionogi.com/us/en/news/2018/1024.html
6. https://www.cdc.gov/flu/treatment/what-to-do-if-you-get-sick.htm
7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689148/
8. https://www.rxlist.com/xofluza-drug.htm
9. https://www.cdc.gov/flu/treatment/viralflexibility.htm
10. https://www.drugpatentwatch.com/